DDInter606 DDInter1376
Droxidopa is a precursor of noradrenaline that is used in the treatment of Parkinsonism. It is approved for use in Japan and is currently in trials in the U.S. The racaemic form (dl-threo-3,4-dihydroxyphenylserine) has also been used, and has been investigated in the treatment of orthostatic hypotension. There is a deficit of noradrenaline as well as of dopamine in Parkinson's disease and it has been proposed that this underlies the sudden transient freezing seen usually in advanced disease. Though L-DOPS has been used in Japan and Southeast Asia already for some time, it is also currently in clinical trials at the phase III point in the United States (U.S.), Canada, Australia, and throughout Europe. Provided L-DOPS successfully completes clinical trials, it could be approved for the treatment of neurogenic orthostatic hypotension (NOH) as early as 2011.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Droxidopa {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Epinephrine
Droxidopa {u} (Compound) resembles {v} (Compound) Mesalazine
Droxidopa {u} (Compound) binds {v} (Gene) DDC
Droxidopa {u} (Compound) is included by {v} (Pharmacologic Class) Increased Blood Pressure
Droxidopa {u} (Compound) causes {v} (Side Effect) Blood pressure increased
Droxidopa {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Isometheptene
Droxidopa {u} may lead to a major life threatening interaction when taken with {v} Cocaine
Droxidopa may cause a moderate interaction that could exacerbate diseases when taken with Epinephrine
Droxidopa (Compound) resembles Mesalazine (Compound)
Droxidopa (Compound) binds DDC (Gene)
Droxidopa (Compound) is included by Increased Blood Pressure (Pharmacologic Class)
Droxidopa (Compound) causes Blood pressure increased (Side Effect)
Droxidopa may cause a moderate interaction that could exacerbate diseases when taken with Isometheptene
Droxidopa may lead to a major life threatening interaction when taken with Cocaine